Compstatin, a peptidic C3 inhibitor, is considered a promising drug and is currently in clinical trials for the treatment of age-dependent macular dystrophia (169) . Since compstatin has proven to be effective in various animal models for other conditions (170) , its application does not appear to be limited to agedependent macular dystrophia.